Clinical Research Center, University Hospital Basel
Basel, Canton of Basel-City, 4031, Switzerland
NCT Number: NCT00822003
The investigators aimed to investigate the pharmacokinetic and pharmacodynamic effects of a single dose (2 mg) of oral GLP-1 administered prior to an oral glucose tolerance test (oGTT) in 16 healthy males
Looking for future studies?
Notify Me18 year–40 year
Male
Interventional
Phase 1 / Phase 2
Basel, Canton of Basel-City, 4031, Switzerland
Background: Glucagon like peptide-1 (GLP-1) promotes satiety and reduces food intake. GLP-1 is secreted from intestinal L-cells into the splanchnic circulation, it is (i) subject to rapid breakdown and (ii) submitted to a high liver extraction. Highest concentrations of GLP-1 are therefore found in the splanchnic blood rather than in the systemic circulation. An oral delivery system would mimick the physiological path of endogenous secretion. Objective: We aimed to investigate the pharmacokinetic and pharmacodynamic effects of a single dose (2 mg) of oral GLP-1 administered prior to an oral glucose tolerance test (oGTT) in 16 healthy males.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
GLP-1 tablet (2mg)
Control tablet
University Hospital, Basel, Switzerland
Other
Effects of Oral GLP-1 on Glucose Homeostasis and Appetite Profile Following an Oral Glucose Tolerance Test in Healthy Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07194772
Glucose Homeostasis, Glucose Intolerance
Ottawa, Ontario, Canada
View Trial DetailsNCT02031497
Behavior, Glucose Homeostasis
Rennes, France
View Trial DetailsNCT07169591
Glucose Homeostasis, Glucose Metabolism Disorders
Hamilton, Ontario, Canada
View Trial DetailsNCT06686888
Glucose Homeostasis, Intestinal Absorption
Leuven, Belgium
View Trial Details